^
    Back
    Association details:
    Biomarker:CLPTM1L expression
    Cancer:Cervical Cancer
    Drug:cisplatin (DNA synthesis inhibitor) +
    paclitaxel (Tubulin inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Oncol Lett
    Title:

    CLPTM1L expression predicts recurrence of patients with intermediate‑ and high‑risk stage IB‑IIB cervical cancer undergoing radical hysterectomy followed by TP as adjuvant chemotherapy

    Published date:
    07/04/2023
    Excerpt:
    In conclusion, the present study revealed that CLPTM1L expression may be a predictive biomarker of recurrence of intermediate- and high-risk stage IB-IIB cervical cancer in patients undergoing radical hysterectomy followed by TP as adjuvant chemotherapy.
    DOI:
    10.3892/ol.2023.13939.